drugset / Trial / NCT02209597

Clinical Study of Generic and Brand Bupropion in Depression

NCT02209597

Phase 4 Completed 74 enrolled Washington University School of Medicine
RandomizedSequentialDouble-blindTreatment

Summary

Determine bioequivalence between branded and generic bupropion extended release (XL) products (and between generic products) at steady state in patients with major depressive disorder.

Timeline

Start
2014-06-25
Primary completion
2016-08-14
Completion
2016-08-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupropion Small molecule 300 mg